2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Locatelli, F. Articles by Andrulli, S. Search for Related Content PubMed PubMed Citation Articles by Locatelli, F. Articles by Andrulli, S.

Is It the Agent or the Blood Pressure Level that Matters for Renal Protection in Chronic Nephropathies?

Department of Nephrology and Dialysis, Ospedale A. Manzoni, Lecco, Italy.

Correspondence to Prof. Dr. Francesco Locatelli, Department of Nephrology and Dialysis, Ospedale A. Manzoni, Via dell’Eremo 9, 23900 Lecco, Italy. Phone: 39-0341-489861; Fax: +39-0341-489860;

ABSTRACT. Some antihypertensive agents may be capable of reducing chronic renal insufficiency (CRI) progression because they halt some of the pathogenic mechanisms involved in renal damage. Although this effect seems to be partially independent of BP reduction, it is still unclear whether these drugs are really superior to other antihypertensive agents when the BP values recommended by the present guidelines are actually achieved. This is particularly true when considering that, in published trials, target and achieved BP values were constantly higher than those nowadays recommended. Furthermore, in the majority of these studies, patients treated with ACE-inhibitors (ACE-I) or Angiotensin II receptor antagonists (ATIIRA) achieved lower BP values than those in control groups and BP values during 24 h were not recorded. Anyway, taking into account the role of baseline and follow-up BP values, the treatment effect remained significant in almost all of the multivariate models. These findings suggest that the renoprotective effect of these agents (ACE-I, ATIIRA) is partially independent of better BP control. However, caution should be paid in attributing true biologic renoprotective properties to drugs just on the basis of statistical adjustments of BP values, although robustly performed, without being aware of what those BP values actually reflect. E-mail: nefrologia@ospedale.lecco.it

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673